Boothbay Fund Management’s Ovid Therapeutics OVID Stock Holding History

Boothbay Fund Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.98M	Sell	737,758 -190,155	-20%	-$491K	0.03%	724
2026 Q1	$2.06M	Buy	927,913 +772,172	+496%	+$1.38M	0.03%	605
2025 Q4	$254K	Sell	155,741 -331,136	-68%	-$510K	﹤0.01%	1531
2025 Q3	$633K	Buy	+486,877	New	+$422K	0.01%	1039
2022 Q2	–	Sell	-71,489	Closed	-$224K	–	2559
2022 Q1	$224K	Hold	71,489	–	–	0.01%	1820
2021 Q4	$229K	Sell	71,489 -40,555	-36%	-$139K	0.01%	1415
2021 Q3	$376K	Sell	112,044 -29,389	-21%	-$107K	0.01%	1221
2021 Q2	$553K	Buy	141,433 +9,599	+7%	+$37.9K	0.02%	952
2021 Q1	$530K	Buy	+131,834	New	+$438K	0.02%	916
2020 Q2	–	Sell	-58,368	Closed	-$174K	–	1074
2020 Q1	$174K	Sell	58,368 -17,370	-23%	-$58.5K	0.01%	677
2019 Q4	$314K	Sell	75,738 -3,657	-5%	-$11.5K	0.03%	595
2019 Q3	$257K	Buy	+79,395	New	+$180K	0.02%	610

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Boothbay Fund Management's OVID Position: Q2 2026 in Review

Boothbay Fund Management reduced its Ovid Therapeutics (OVID) stake by 20% in Q2 2026, selling an estimated $491K and leaving 737,758 shares worth $1.98M. The position accounts for 0.03% of the portfolio, ranked #724.

Boothbay Fund Management first reported a position in OVID in Q3 2019 and has held it in 12 quarters since. The position peaked at $2.06M in Q1 2026. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

Boothbay Fund Management held 737,758 shares of Ovid Therapeutics worth $1.98M as of Q2 2026.
Boothbay Fund Management sold 190,155 Ovid Therapeutics shares in Q2 2026, an estimated $491K.
Ovid Therapeutics made up 0.03% of Boothbay Fund Management's portfolio in Q2 2026, its #724 holding.
Boothbay Fund Management first reported a position in Ovid Therapeutics in Q3 2019 and has held it in 12 quarters since.
Boothbay Fund Management's Ovid Therapeutics position peaked at $2.06M in Q1 2026.
130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.